Table 1 Clinical and histopathological characteristics of 132 healthy controls and 144 breast cancer patients
From: Clinical significance of serum PSA in breast cancer patients
Healthy control (n = 132) | Breast cancer (n = 144) | ||
|---|---|---|---|
No of cases (%) | No of cases (%) | ||
Age (mean ± SD) | 53.1 ± 10.7 | 62.9 ± 13.2 | |
Menopausal status | Pre-menopausal | 61 (46.2) | 27 (18.8) |
Post-menopausal | 71 (53.8) | 117 (81.3) | |
sPSA detection rate | 25.8% | 29.2% | |
sPSA ng/l (Median [IQR*]) | 0 (0–3) | 0 (0–4) | |
Clinical stage | Non-MBC; Stage 0-III | – | 67 (46.5) |
MBC; Stage IV, Recurrence | – | 77 (53.5) | |
Histological type | Invasive ductal carcinoma | – | 102 (70.8) |
Ductal carcinoma in situ | – | 9 (6.3) | |
Invasive lobular carcinoma | – | 11 (7.6) | |
Lobular carcinoma in situ | – | 0 (0) | |
Special type | – | 22 (15.3) | |
Subtype | Luminal; ER+ / HER2- | – | 99 (68.8) |
Luminal HER2; ER+ / HER2+ | – | 16 (11.1) | |
HER2 enriched; ER- / HER2+ | – | 8 (5.6) | |
TNBC; ER- / HER2- | – | 21 (14.6) | |
Histological grade | 1 | – | 82 (56.9) |
2 | – | 40 (27.8) | |
3 | – | 22 (15.3) | |
Ki67 positivity | < 20% | – | 60 (41.7) |
≧20% | – | 81 (56.3) | |
Unknown | – | 3 (2.1) | |